WARREN, N.J. (AP) — WARREN, N.J. (AP) — Aquestive Therapeutics Inc. (AQST) on Wednesday reported a loss of $17.1 million in its fourth quarter.
On a per-share basis, the Warren, New Jersey-based company said it had a loss of 19 cents.
The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 14 cents per share.
The specialty pharmaceutical company posted revenue of $11.9 million in the period, which also fell short of Street forecasts. Five analysts surveyed by Zacks expected $13.5 million.
For the year, the company reported that its loss widened to $44.1 million, or 51 cents per share. Revenue was reported as $57.6 million.
Aquestive Therapeutics expects full-year revenue in the range of $47 million to $56 million.
In the final minutes of trading on Wednesday, the company's shares hit $2.81. A year ago, they were trading at $4.19.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AQST at https://www.zacks.com/ap/AQST
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。